Should I buy or sell Gracell Biotechnologies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares. View GRCL analyst ratings or view top-rated stocks .

What is Gracell Biotechnologies' stock price target for 2024?

8 Wall Street analysts have issued 1 year price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $13.04 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts .

How have GRCL shares performed in 2024?

Gracell Biotechnologies' stock was trading at $10.04 on January 1st, 2024. Since then, GRCL shares have increased by 2.1% and is now trading at $10.25. View the best growth stocks for 2024 here .

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.18. The company had revenue of $0.06 million for the quarter.

When did Gracell Biotechnologies IPO?

Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GRCL

Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free GRCL Stock Alerts

$10.25

0.00 (0.00%)

(As of 02/22/2024)

Compare

Today's Range: $10.25
▼
$10.25
50-Day Range: $10.14
▼
$10.35
52-Week Range: $1.40
▼
$10.44

Volume: N/A
Average Volume: 1.32 million shs
Market Capitalization: $744.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.04

Get Gracell Biotechnologies alerts:

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

GRCL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRCL Stock News Headlines

March 3, 2024 | finance.yahoo.com

GRCL Mar 2024 10.000 call(CONTR

February 22, 2024 | finance.yahoo.com

Gracell Biotechnologies Acquisition Completed

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

February 22, 2024 | globenewswire.com

Gracell Biotechnologies Acquisition Completed

February 21, 2024 | seekingalpha.com

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

February 21, 2024 | investing.com

Gracell Biotechnologies Inc. (GRCL)

February 20, 2024 | finanznachrichten.de

Gracell Biotechnologies Inc.: Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

February 20, 2024 | finance.yahoo.com

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

February 20, 2024 | globenewswire.com

Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

February 17, 2024 | finance.yahoo.com

GRCL Mar 2024 2.500 call

February 17, 2024 | seekingalpha.com

GRCL Gracell Biotechnologies Inc.

January 29, 2024 | finance.yahoo.com

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

January 3, 2024 | finance.yahoo.com

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?

December 31, 2023 | businesswire.com

GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

December 27, 2023 | markets.businessinsider.com

Maintaining Hold on Gracell Biotechnologies Amidst AstraZeneca Acquisition Prospects

December 26, 2023 | msn.com

Why China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring Today

December 26, 2023 | finance.yahoo.com

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023 | markets.businessinsider.com

Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session

December 26, 2023 | tmcnet.com

GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders

December 21, 2023 | finance.yahoo.com

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

December 21, 2023 | finance.yahoo.com

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why

December 12, 2023 | finance.yahoo.com

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

December 11, 2023 | finance.yahoo.com

Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade

December 2, 2023 | finance.yahoo.com

Institutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the company

November 29, 2023 | markets.businessinsider.com

Buy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy Advancements

November 28, 2023 | msn.com

Evercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform Recommendation

See More Headlines

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:GRCL
CUSIP: N/A
CIK: 1826492
Web: www.gracellbio.com
Phone: 86-512-6262-6701
Fax: N/A
Employees: 314
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.04
High Stock Price Target: $20.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +27.2%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -37.40%
Return on Assets: -31.24%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 7.73
Quick Ratio: 7.73

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 12,415.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.95 per share
Price / Book: 3.47

Miscellaneous

Outstanding Shares: 72,678,000
Free Float: 52,328,000
Market Cap: $744.95 million
Optionable: Optionable
Beta: -0.33

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Wei Cao BM (Age 65)
Ph.D., Founder, Chairman & CEO
Dr. Yili Xie M.B.A. (Age 53)
Ph.D., Chief Financial Officer
Dr. Samuel Suhua Zhang M.B.A. (Age 56)
Ph.D., Chief Business Officer
Dr. Wendy Li M.D. (Age 65)
Chief Medical Officer
Ms. Erin Li
Executive Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GRCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRCL, but not buy additional shares or sell existing shares.
View GRCL analyst ratings or view top-rated stocks.
What is Gracell Biotechnologies' stock price target for 2024?: 8 Wall Street analysts have issued 1 year price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $13.04 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts.
How have GRCL shares performed in 2024?: Gracell Biotechnologies' stock was trading at $10.04 on January 1st, 2024. Since then, GRCL shares have increased by 2.1% and is now trading at $10.25.
View the best growth stocks for 2024 here.
How were Gracell Biotechnologies' earnings last quarter?: Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.18. The company had revenue of $0.06 million for the quarter.

When did Gracell Biotechnologies IPO?: Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.
How do I buy shares of Gracell Biotechnologies?: Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRCL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

GRCL Stock Price History

GRCL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

GRCL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info